Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B

Objective: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic breakthrough (VB) after emergence of YMDD mutants in CHB patients receiving lamivudine. Methods: Ninety-three consecutive HBeAg-positive CHB patients treated with lamivudine (100 mg/day) who developed YMDD mutants and VB were enrolled. The clinical breakthrough (CB) was defined by elevation of alanine aminotransferase (ALT) >2 times the upper limit of normal. Results: The median age was 47 years, and genotype of hepatitis B virus (HBV) was all C. The median duration of lamivudine administration was 39 months, and median pre-lamivudine ALT and HBV DNA were 165 IU/l and 1.2 × 108 copies/ml. In all patients, CB concurred with VB or appeared some months following VB. When patients were divided into two groups according to time sequence of two breakthroughs – group 1 (VB followed by CB, n = 68) and group 2 (concurrent VB and CB, n = 25) – there was no difference in patient and virologic characteristics between the two groups. The median time from VB to CB was 8 months in group 1. Conclusion: VB might eventually progress to CB in HBeAg-positive patients harboring YMDD mutants with high pretreatment ALT and HBV DNA.

[1]  M. Manns,et al.  Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. , 2007, Zeitschrift fur Gastroenterologie.

[2]  P. Lampertico,et al.  Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. , 2007, Gastroenterology.

[3]  Ling-xia Zhang,et al.  [AASLD practice guidelines: chronic hepatitis B]. , 2007, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[4]  B. McMahon,et al.  Corrections to AASLD guidelines on chronic hepatitis B , 2007 .

[5]  J. Hoofnagle,et al.  Management of hepatitis B: Summary of a clinical research workshop , 2007, Hepatology.

[6]  S. Sarin,et al.  Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long‐term lamivudine therapy , 2006, Journal of gastroenterology and hepatology.

[7]  M. Yuen,et al.  Significance of Viral Load, Core Promoter/Precore Mutations and Specific Sequences of Polymerase Gene in Hbv-Infected Patients on 3-Year Lamivudine Treatment , 2006, Antiviral therapy.

[8]  Y. Paik,et al.  The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B , 2005, Antiviral therapy.

[9]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[10]  H. Lee,et al.  Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long‐term lamivudine therapy , 2005, Journal of gastroenterology and hepatology.

[11]  S. Ahn,et al.  Evaluation of Methods for Monitoring Drug Resistance in Chronic Hepatitis B Patients during Lamivudine Therapy Based on Mass Spectrometry and Reverse Hybridization , 2005, Antiviral therapy.

[12]  B. Song,et al.  Hepatitis B Virus Genotypes in Korea: An Endemic Area of Hepatitis B Virus Infection , 2005, Intervirology.

[13]  R. Goldin,et al.  Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. , 2005, Journal of hepatology.

[14]  S. Ahn,et al.  [Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry]. , 2004, The Korean journal of hepatology.

[15]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[16]  M. Yuen,et al.  Long-Term Follow-Up Study of Chinese Patients with YMDD Mutations: Significance of Hepatitis B Virus Genotypes and Characteristics of Biochemical Flares , 2004, Journal of Clinical Microbiology.

[17]  N. Kim,et al.  Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. , 2004, Journal of hepatology.

[18]  S. Hadziyannis,et al.  Course of virologic breakthroughs under long‐term lamivudine in HBeAg‐negative precore mutant HBV liver disease , 2002, Hepatology.

[19]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[20]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[21]  C. Hui,et al.  Factors Predicting Hepatitis B Virus DNA Breakthrough in Patients Receiving Prolonged Lamivudine Therapy , 2001 .

[22]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[23]  S. Ahn,et al.  Association between hepatitis B virus infection and HLA‐DR type in Korea , 2000, Hepatology.

[24]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[25]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[26]  M Lindh,et al.  Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method. , 1997, The Journal of infectious diseases.

[27]  K. Reddy,et al.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.

[28]  D. Tyrrell,et al.  Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo , 1996, Hepatology.

[29]  Ding‐Shinn Chen,et al.  From hepatitis to hepatoma: lessons from type B viral hepatitis. , 1993, Science.